Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 6 de 6
1.
Clin Case Rep ; 9(4): 2453-2459, 2021 Apr.
Article En | MEDLINE | ID: mdl-33936712

Monitoring venous congestion by ultrasound assessment of hepatic venogram allowed individualized fluid management in severe cardiorenal syndrome type 5 due to light chain myeloma, preserving residual renal function and avoiding heart failure.

2.
Tumori ; 106(6): NP23-NP28, 2020 Dec.
Article En | MEDLINE | ID: mdl-32851941

INTRODUCTION: Head and neck cancer represents a variety of tumors involving different organs in the cervical district, burdened by poor prognosis when diagnosed in an advanced stage. Immunotherapy with both anti-PD-1 nivolumab and pembrolizumab has the aim of increasing overall survival for patients with this malignancy. We report the first case of immune-related encephalitis caused by nivolumab in this setting of disease and present a brief review of the literature. CASE DESCRIPTION: A 60-year-old woman had been treated with concomitant chemoradiotherapy for a locally advanced human papillomavirus-negative squamous cell carcinoma of the tonsil. After local recurrence, she was treated with platinum-based first-line chemotherapy, followed by nivolumab at further progression within 6 months. Nivolumab was administered for 19 weeks, then discontinued due to the occurrence of immune-related hypothyroidism and grade 2 diarrhea. A month after the onset of the endocrinopathy, the patient also developed steroid-responsive encephalitis, considered as a consequence of anti-PD-1 therapy. One year after discontinuation of immunotherapy, toxicities have resolved and the patient is maintaining a complete radiologic response. CONCLUSIONS: Immunotherapy is a relatively new and promising therapy in the field of oncology. Its mechanism of action, which aims to stimulate the immune system against cancer cells, is not comparable to systemic and cytotoxic chemotherapy, which directly attacks and destroys malignant cells. Despite these differences, immunotherapy is not to be considered free from side effects, sometimes life-threatening.


Antineoplastic Agents, Immunological/adverse effects , Autoimmune Diseases/etiology , Encephalitis/etiology , Head and Neck Neoplasms/complications , Nivolumab/adverse effects , Antineoplastic Agents, Immunological/therapeutic use , Autoimmune Diseases/diagnosis , Autoimmune Diseases/therapy , Electroencephalography , Encephalitis/diagnosis , Encephalitis/therapy , Female , Head and Neck Neoplasms/diagnosis , Head and Neck Neoplasms/drug therapy , Humans , Immunosuppressive Agents/therapeutic use , Middle Aged , Molecular Targeted Therapy , Neoadjuvant Therapy/methods , Neoplasm Staging , Nivolumab/therapeutic use , Positron-Emission Tomography , Tomography, X-Ray Computed
4.
Anticancer Drugs ; 27(2): 144-6, 2016 Feb.
Article En | MEDLINE | ID: mdl-26469836

Skin toxicity is a frequent complication of anti-epidermal growth factor receptor therapy, which can be an obstacle in maintaining the dose intensity and may negatively impact on the clinical outcome of cancer patients. Skin lesions depend on the disruption of the keratinocyte development pathways and no treatment is clearly effective in resolving the cutaneous alterations frequently found during anti-epidermal growth factor receptor therapy. Among systemic treatments, oral tetracycline proved to be useful in preventing skin manifestations. We describe the case of a patient affected by metastatic colorectal cancer, for whom a combination of chemotherapy and cetuximab was used as second-line treatment. The patient developed a symptomatic papulopustular skin rash that disappeared completely after a twice-daily application of a hydrating and moisturizing cream, mainly consisting of a mixture of paraffin, silicone compounds, and macrogol. The marked cutaneous amelioration allowed the patient to continue cetuximab without any further symptoms and was associated with a partial radiological response.


Antineoplastic Combined Chemotherapy Protocols/adverse effects , Colorectal Neoplasms/drug therapy , ErbB Receptors/antagonists & inhibitors , Exanthema/therapy , Skin Cream/therapeutic use , Skin/drug effects , Bevacizumab/administration & dosage , Cetuximab/administration & dosage , Colorectal Neoplasms/pathology , Female , Humans , Middle Aged , Neoplasm Metastasis
5.
Cancers Head Neck ; 1: 16, 2016.
Article En | MEDLINE | ID: mdl-31093345

BACKGROUND: Oropharyngeal cancer is frequently associated with human papilloma virus, that also represents a strong prognostic factor. Local relaps and treatment-related complications are frequent, whereas distant metastases occur in about 25% of patients. CASE PRESENTATION: A 49 years-old male presented with a loco-regionally advanced oropharyngeal squamous cell carcinoma and was treated with concomitant chemoradiation. A complete clinical and pathological response was achieved, but the occurrence of necrotising tracheo-esophagitis, with tracheo-mediastino-pleural fistula formation, further complicated the subsequent clinical course. The patient died suddenly. Autopsy revealed multiple myocardial and epicardial metastases from oropharyngeal squamous cell carcinoma. CONCLUSIONS: Even in case of a transient complete local response, the potential occurrence of severe complications and distant metastases, although infrequent, should be considered. Cardiac metastases are frequently underestimated, as they are often asymptomatic, but may lead to sudden death. Further efforts are needed to improve diagnosis and therapy in this setting.

6.
Med Oncol ; 31(9): 171, 2014 Sep.
Article En | MEDLINE | ID: mdl-25134917

Osteosarcomas of the jaws are rare mesenchymal tumors frequently diagnosed in the fourth decade of life which account for 6 % of all osteosarcomas. This study evaluated the efficacy on the patients outcome of multimodality treatment consisting of surgery, chemotherapy and radiotherapy. The records of 22 patients affected by jaw osteosarcoma treated with a combination of surgery, poly-chemotherapy and adjuvant radiotherapy in selected cases were reviewed. Response rate, progression-free survival and overall survival were evaluated. Neoadjuvant chemotherapy resulted in an overall response rate of 83.3 %, necrosis of grade I or II was obtained, respectively, in 44.4 and 55.6 % of the patients, and surgery was radical in all patients. At a median follow-up of 60 months, the 5-year progression-free survival and overall survival were 73.5 and 77.4 %, respectively. These outcome parameters significantly correlated with age at diagnosis and grade of chemotherapy-induced necrosis. A complex multimodality approach including chemotherapy and radiotherapy, along with radical surgery, can maximize the outcome of patients affected by osteosarcoma of the jaws.


Jaw Neoplasms/epidemiology , Jaw Neoplasms/therapy , Osteosarcoma/epidemiology , Osteosarcoma/therapy , Adolescent , Adult , Aged , Antineoplastic Agents/therapeutic use , Chemoradiotherapy, Adjuvant , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Prognosis , Plastic Surgery Procedures , Retrospective Studies , Young Adult
...